key: cord-1012523-nj86pa5b
authors: JJ, Sánchez; N, Acevedo; E, Guzmán
title: Active smoking and severity of coronavirus disease 2019 (COVID-19): Differences in measurement of variables could cause errors in the results.
date: 2020-05-28
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2020.05.033
sha: dc30d4664a2c2d20c4133dbbb23ef60fc78f580a
doc_id: 1012523
cord_uid: nj86pa5b

nan

In this letter to the editor, we would like to address some main points presented in the manuscript by Lippi G, and Henry BM. [1] regarding smoking as a risk factor for SARS-CoV-2. Even though the author suggested that ACE2 receptors are diminished in severe acute respiratory syndrome patients (SARS-CoV-1), this does not seem to apply to SARS-CoV-2 patients. Actual studies reporting the molecular characteristics of the lungs of smokers indicate that ACE2 receptors seem to be upregulated in both current and former smokers with SARS-CoV-2. This data gathered from both Asian and European patients also suggests otherwise, and supports that since ACE2 receptors promote viral entry into epithelial lung cells via a spike glycoprotein, and smokers show an upregulation of this receptor into the lung tissue, smoking could therefore be increasing the risk of infection in this population [2, 3] . About disease progression, it has been proposed that smoking combined with ACE2 deficiency promotes lung injury through inflammation and vascular permeability, which clearly is not compatible with the author's ideas [4] . pneumonia was smoking history 3/5 (27.3%) compared to 2/5 (3.0%) in those who did not have a smoking history with a statistically significant value of P = 0.018. However, the measured variable was smoking history, current non-smoker, this measure being dichotomous, yes or no. D. Yang X et al, 2020 [8] , meanwhile, measured the variable smoking in a study population of 52 critically ill participants, with only 2 current smokers participating, and the response variable was survivor or non-survivor, which is a different progression of the disease assessed in other studies. E. In the study by Zhang JJ et al, 2020 [9] , the limitation with current smokers is mentioned, being 2/140 (1.4%) current smokers and 7/140 (5.0%) ex-smokers. The 2 current smokers had severe disease. We agree with the information provided in the letter to the editor prepared by Ernest L and Benoit L (10) where the high variability in the meta-analysis of Lippi et al (1) is highlighted, this being reflected in the wide intervals of confidence, preventing the ruling out of a clinical association. Authors indicate that a more appropriate conclusion for this study is that, due to lack of sample size, the effect of smoking on COVID-19 severity remains highly possible.

Non-significant P values in the evaluated studies and the results of the meta-analysis do not necessarily rule out the association between the use of tobacco products and COVID-19 severity.

Moreover, pooled OR analysis shows potential bias since the risk factor assessed within the individual data is categorize using different criteria. These results motivate us to analyze the different studies considering the limited number of current smokers in each study, the discrepancies in which the main variable "current smoker" was measured (See table 1 ) and multivariable analysis to estimate the effect of smoking exposure. Furthermore, the response variables were not the same in the different studies, since some assessed disease severity and others survival. Another restraint not mentioned in the articles included, is the frequency of tobacco use and the time being a current smoker, as an important indicator used to predict disease severity, since an occasional user is not to be compared to a frequent user with a history 20 years of tobacco use in terms of morphological and pathophysiological modifications.

Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)

A Hint on the COVID-19 Risk: Population Disparities in Gene Expression of Three Receptors of SARS-CoV

ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19. The European Respiratory Journal

Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine

Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan

Active smoking and severity of coronavirus disease 2019 (COVID-19): The use of significance testing leads to an erroneous conclusion

The authors declare they have no conflict of interest.